Evogene Ltd. Reports Q1 2025 Financial Results
Ticker: EVGN · Form: 6-K · Filed: May 21, 2025 · CIK: 1574565
Sentiment: neutral
Topics: financial-results, quarterly-report, form-6k
TL;DR
Evogene dropped Q1 2025 earnings on May 21st. Check the 6-K for details.
AI Summary
Evogene Ltd. announced its financial results for the first quarter ended March 31, 2025, on May 21, 2025. The company, headquartered in Rehovot, Israel, is a foreign private issuer filing a Form 6-K report. This filing includes a press release detailing the first quarter financial performance.
Why It Matters
This filing provides investors with an update on Evogene's financial performance for the first quarter of 2025, allowing them to assess the company's current financial health and operational progress.
Risk Assessment
Risk Level: low — This is a routine financial results disclosure, not indicating new significant risks.
Key Players & Entities
- Evogene Ltd. (company) — Registrant
- March 31, 2025 (date) — End of first quarter
- May 21, 2025 (date) — Date of announcement and filing
- Rehovot, Israel (location) — Company headquarters
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report Evogene Ltd.'s financial results for the first quarter ended March 31, 2025, via an attached press release.
When did Evogene Ltd. announce its first quarter financial results?
Evogene Ltd. announced its financial results for the first quarter ended March 31, 2025, on May 21, 2025.
What is the filing date of this Form 6-K?
This Form 6-K was filed as of May 21, 2025.
Where is Evogene Ltd. headquartered?
Evogene Ltd. is headquartered at 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel.
What exhibit is included with this Form 6-K?
Exhibit 99.1, a press release announcing the first quarter financial results, is furnished with this Form 6-K.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 21, 2025 regarding Evogene Ltd. (EVGN).